ArticlePediatrics international : official journal of the Japan Pediatric Society
Ascertaining the Kawasaki Disease-Coronavirus Disease 2019 Linkage in a Japanese Administrative Claims Database.
Article in Pediatrics international : official journal of the Japan Pediatric Society. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A possible shared 4-6-week latency between MIS-C and Kawasaki disease: epidemiological insights from Japan.Pediatric research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundDespite the potential association between Kawasaki Disease (KD) and coronavirus disease 2019 (COVID-19), real-world clinical associations remain unclear. We aimed to investigate the association between KD and COVID-19 using a Japanese claims database.
methodsUsing a Japanese claims database, we identified patients diagnosed with COVID-19 between January 1, 2020, and December 31, 2022 and conducted the following two analyses: a nested case-control study wherein each KD case was matched 1:4 to controls (without KD), and conditional logistic regression analyses were used to calculate odds ratios (ORs) for COVID-19 exposure in the previous 1-30, 31-60, and 61-90 days. In the self-controlled case-series (SCCS) analysis, the observation comprised the 120 days before and after COVID-19 diagnosis (Day 0). We calculated the incidence rate ratio (IRR) of three risk periods (Days 1-30, 31-60, 61-90) after Day 0 compared with the control periods.
resultsNested case-control analysis matched 134 cases with 536 controls. COVID-19 exposure was identified in 26.1% (35/134) of cases and 7.3% (39/536) of controls during the previous 1-30 days (adjusted OR 7.8, 95% CI 3.2-19), and in 18.7% (25/134) and 8.8% (47/536) during the previous 31-60 days (adjusted OR 3.6, 95% CI 2.0-6.5). SCCS analysis included 124 patients, revealing elevated IRRs on Days 1-30 (95% CI: 11 [6.0-20]), and 31-60 (6.9 [3.6-13]) after COVID-19 diagnosis.
conclusionThe present study found that COVID-19 was associated with the development of KD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.